THE Denmark will grant COVID-19 vaccines in children aged 12 to 15 years after vaccinating the adult population to boost collective immunity against the virus in the face of winter, health authorities announced today.
Denmark will initially only administer the Pfizer-BioNTech product to children aged 12-15 as it is the only vaccine approved by the EU drug regulator for adolescents, the Danish Health Authority said in a statement.
At the end of May, the EU drug regulator gave the green light to BioNTech COVID-19 vaccine for use in children up to 12 years old, and its decision to use the Moderna vaccine in adolescents is expected to be announced sometime within next month.
“The extension of vaccinations to children aged 12-15 is necessary to ensure even greater immunity in the population and therefore to control the pandemic in Denmark,” said the head of the Danish Health Authority, Zoren Brosstrom.
The vaccination of the teenagers will start after the last adults have been fully vaccinated, in the middle of September, he said during the press briefing.
“We need collective immunity, especially before winter”, he added.
Denmark: The country that shook the waters when it announced the cessation of vaccinations of AstraZeneca and Johnson & Johnson
Denmark shook waters when it announced in April and May that it would suspend AstraZeneca vaccines and Johnson & Johnson because of their possible association with a rare but serious form of thrombosis.
The government of this Scandinavian country has since asked the health authorities to reconsider the exclusion of these vaccines since new data on their action and side effects were reported.
Almost half of the Danish population has been vaccinated with the first dose, and more than a quarter of the population is fully vaccinated.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
